Evidence map›Paper›PMID 27449972›Full record

ReviewCold Spring Harbor perspectives in medicine2016

Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

David C Hooper, George A Jacoby

Open access · bronzeAbstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 268 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
268citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

268 citing papers in PubMed, 1 synthesis or guideline pooled it, 508 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Thermal Shifts Dominate Single-Gene Responses to Transcription-Targeting Antibiotics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Article
  5. Article
  6. Antibacterial photoswitchable triazenic ciprofloxacins.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Article
  7. Article
  8. Antibiotic resistance mechanisms and global resistance patterns of Pseudomonas aeruginosa in microbial keratitis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Methicillin-ResistantInternational journal of molecular sciences · 2026
    Review
  16. Article
  17. Review
  18. Protective role of VitC, Glutathione and Sodium Pyruvate against antibiotic-induced oxidative damage in Escherichia coli.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  19. Article
  20. Review

208 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

David C HooperDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114.
George A JacobyLahey Hospital and Medical Center, Burlington, Massachusetts 01805.
Lahey Hospital and Medical Center · USMassachusetts General Hospital · US

Funding

Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI David C Hooper · 2009 to 2026
$39.4M
Plasmid-mediated Quinolone ResistanceR01AI057576 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HOOPER, DAVID C · 2004 to 2018
$5.3M
Quinolone and multidrug resistance in Staphylococcus aureusR37AI023988 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HOOPER, DAVID C · 2008 to 2017
$4.1M
QUINOLONE RESISTANCE MECHANISMS IN STAPHYLOCOCCUS AUREUSR01AI023988 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HOOPER, DAVID C · 1986 to 2007
$3.0M
NIAID NIH HHS P01 AI083214NIAID NIH HHS R01 AI023988NIAID NIH HHS R01 AI057576NIAID NIH HHS R37 AI023988
6 · The paper itself

Abstract

Quinolone antimicrobials are widely used in clinical medicine and are the only current class of agents that directly inhibit bacterial DNA synthesis. Quinolones dually target DNA gyrase and topoisomerase IV binding to specific domains and conformations so as to block DNA strand passage catalysis and stabilize DNA-enzyme complexes that block the DNA replication apparatus and generate double breaks in DNA that underlie their bactericidal activity. Resistance has emerged with clinical use of these agents and is common in some bacterial pathogens. Mechanisms of resistance include mutational alterations in drug target affinity and efflux pump expression and acquisition of resistance-conferring genes. Resistance mutations in one or both of the two drug target enzymes are commonly in a localized domain of the GyrA and ParC subunits of gyrase and topoisomerase IV, respectively, and reduce drug binding to the enzyme-DNA complex. Other resistance mutations occur in regulatory genes that control the expression of native efflux pumps localized in the bacterial membrane(s). These pumps have broad substrate profiles that include other antimicrobials as well as quinolones. Mutations of both types can accumulate with selection pressure and produce highly resistant strains. Resistance genes acquired on plasmids confer low-level resistance that promotes the selection of mutational high-level resistance. Plasmid-encoded resistance is because of Qnr proteins that protect the target enzymes from quinolone action, a mutant aminoglycoside-modifying enzyme that also modifies certain quinolones, and mobile efflux pumps. Plasmids with these mechanisms often encode additional antimicrobial resistances and can transfer multidrug resistance that includes quinolones.

Indexed as

Anti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVDrug Resistance, BacterialEscherichia coliFluoroquinolonesHumansMutationPlasmidsTopoisomerase InhibitorsAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVFluoroquinolonesTopoisomerase Inhibitors

Identifiers

PMID27449972
PMCPMC5008060
OpenAlexW2498876603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.